Brief: Syros Pharmaceuticals Q2 EPS USD -0.59 Vs. IBES Estimate USD -0.77
31/07/2024 12:30
Jul 31 (Reuters) - Syros Pharmaceuticals Q2 operating expenses USD 27.416 million. * Q2 net income USD -23.327 million vs. IBES estimate USD -30.6 million * Q2 income from operations USD -27.416 million vs. IBES estimate USD -30.7 million
Recent news on Syros Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Syros falls after blood cancer drug fails in late-stage trial